Objective: To measure and describe patterns of interobserver variation in visual interpretation of FDG PET in malignant lymphoma.
INTRODUCTION
FDG PET has emerged as a powerful functional imaging tool in treatment individualization of aggressive non-Hodgkin lymphoma (NHL) and Hodgkin's disease (HD) 1;2 . At diagnosis, FDG PET improves the assessment of disease burden. 3;4 In evaluation of therapy, FDG PET differentiates viable tumor from fibrosis in residual masses after chemotherapy. Furthermore, several studies have suggested its use during therapy to identify patients who might benefit from a timely switch to alternative line therapy. 5;6 Although the perspective to implement FDG PET in malignant lymphoma is excellent, some methodological issues remain. PET positivity is based on visual interpretation. However, criteria for test positivity are not uniform in the literature. 7 Moreover, data on observer variation of PET are quite limited. We decided to measure the observer variation, and to identify patterns of error in reading FDG PET scans obtained for staging and therapy evaluation in Hodgkin's and non-Hodgkin's lymphoma.
MATERIALS AND METHODS

Design
Thirty-seven PET scans of lymphoma patients were evaluated on the basis of visual inspection by 11 experienced board-certified nuclear medicine physicians who had a variable experience with PET: five had interpreteted between 750-1250 PET scans in their own practice (further indicated as 'the e-group'); the remaining six had no personal PET experience ('the i-group').
All had taken PET courses in the institute of the expert nuclear medicine physicians and CME courses of the SNM and EANM. Their results were compared with the combined judgement of two expert nuclear medicine physicians (EC, OSH), both with over a decade of PET experience, reviewing > 8000 PET scans. The readings of these experts were used as the gold standard. The whole body PET scans were randomly chosen from the PET referral database of the VUmc (VU University Medical Centre, Amsterdam, The Netherlands), and from prospective studies. 8 Ten scans had been obtained in newly diagnosed HD (n=7) and NHL patients (n=3), at presentation. Fifteen scans were midtreatment scans (4 HD, 11 NHL) for monitoring therapy response, and the remaining 12 scans had been performed to evaluate completed first-line chemotherapy (3 HD, 9 NHL).
PET scans had been performed using a full ring BGO scanner (ECAT EXACT HR + , CTI/ Siemens), in 2D mode, with emission scans of 5 min/bed, starting 60 min after 370 MBq FDG administration, and typically covering a scan trajectory of mid-femur to skull. The scans were corrected for decay, scatter, and randoms, and reconstructed using ordered Chapter 4 subset expectation maximization (OSEM) with two iterations and 16 subsets followed by post-smoothing (Hanning 0,5 filter, transaxial spatial resolution 7 mm fool-width of half maximum).
The observers were provided with the same clinical information accompanying the original PET scan referral, but they had no access to other imaging tests, like CT scans (ie. results of physical examination / CT scans at presentation).
The observers were requested to localize and assess the likelihood of malignancy of any potential lymphoma lesion. The readers used a data sheet to score involvement of 9 nodal sites: neck (right and left side), periclavicular (right and left side), axillary (right and left side), mediastinal and hilar (right and left side), para-aortic (abdominal) and iliac, mesenteric and iguinal (right and left side), as well as five extranodal sites: lung, pleura/pericard (termed "serous" in the analyses), liver, spleen and bone marrow. Abnormalities (vs. normal 18 F-FDG biodistribution) were asked to be classified as positive, negative or equivocal for the presence of viable lymphoma. Each observer independently interpreted the set of scans using a specially designed software tool (running in Matlab 5.3), which allowed simultaneous visualisation of PET images in the axial, coronal and sagittal planes (at 5 or 10 mm slice thickness), with possible cross linking. This software tool had been installed on the personal computer of each observer, and the results were electronically stored for analysis. In order to be able to accurately relate results of different observers, the coordinates of each hot spot identified by any observer were electronically linked to the assigned interpretation. All observers had worked with this software before during a comparable interobserver study in non-small cell lung cancer.
Data analysis
We compared the individual scores with the expert readers in per patient-and per site analyses. For the patient specific analysis in baseline scans, we compared the Ann Arbor In a sensitivity analysis, we compared the results of conservative (i.e. equivocal scores considered to be benign) and sensitive reading (assigning equivocal scores to malignant categories), respectively. was scored in accordance with the experts (conservative reading, vs 45% for sensitive reading).
The experienced observers had slightly better results in patients with remaining active disease (87% correct classifications versus 77% for inexperienced observers with conservative reading, and 97% versus 92% with -sensitive reading). Overstaging in patients without remaining active disease was generally equal for both groups of observers (49% and 51%, respectively) using the conservative assessment strategy and even slightly higher in the experienced group (62% and 49%, respectively) when using the sensitive assessment strategy.
The scans of the 14 patients with active disease harbored a total of 74 involved sites. The experts had no equivocal scores; for the observers the equivocal proportion was higher in the therapy scans (15%) than in the baseline ones (6%). Taken together, the 11 observers scored 554 of the 831 possible tumor sites (67%) in accordance with the expert reading using conservative assessment criteria vs. 73% for sensitive reading. Conservative reading yielded interpreted as pulmonary lesions, leading to false positive readings; bowel and mesenterial nodes, ureters and iliac nodes, both leading to false negative readings), and finally to interpretative errors (reading a new lung lesion after therapy as viable tumour while all known sites had disappeared).
With the baseline PET scans false positivity tended to be higher in the neck area and in the lung compared to the other regions. In the remaining scans, the highest concordances with experts were seen in the periclavicular, axillary and mediastinal regions with a tendency towards relatively more errors in the neck regions, and in either direction (ie. false positives and Obs 3e
Obs 4e
Obs 5e
Obs 6i
Obs 7i
Obs 8i
Obs 9i
Obs 10i
Obs 11i
Neck** n=33 C. C.  3  3  3  2  3  2  2  3  3  2  2   S.  3  3  3  3  3  2  3  3  3  3  3 Mediastinal/ hilar** n=8 C. .  1  2  3  1  2  2  3  2  1  1  2   S.  3  3  3  2  3  3  3  2  2  2  2 Serous n=1 C.
Bone marrow n=4 C. -negatives). False negativity after therapy was seen more often in the mesenterial and inguinal regions, and false positivity more often in the bone marrow (Table 3 and Figure 2 ). Differences between sensitive and conservative readings and thus equivocal scores, were most prominent in the neck, around the abdominal aorta/iliac vessels and in the lung (Table 3) .
DISCUSSION
FDG PET can provide complementary information to conventional procedures such as contrast enhanced CT and bone marrow biopsy, which leads to modification of stage and has impact on management. Impact of PET findings on staging and patient management varies among different reported studies, up to 60% of patients. 9 To our knowledge, this is the first interobserver variation study on PET in lymphoma conducted in a larger group of nuclear medicine physicians. The main findings were a notable observer variation and errors occurring in either direction, albeit leaning to false positivity. Clinical PET experience had less impact than we had expected, and this is why we pooled the data for most of the analyses. We can only speculate about the lack of impact of clinical experience, but suggest Chapter 4 that with lymphoma, clinical feed-back from the haematologist is less likely to affect reading performance since histopathology of the various suspected lesions as verification is not routinely performed, and if so, is not necessarily correct in case of a negative biopsy. This is quite different from the situation in pre-surgical settings like lung cancer. In fact, this was also the reason for using combined expert readings as the reference standard. Agreement was relatively good for mediastinum, hilus, pleura and spleen, but clearly less well for neck and periclavicular area. The latter variability largely results from variable recognition of aspecific uptake in brown fat and muscle 10 , and suggests that observer agreement may improve with a baseline PET scan and/or PET-CT. 11 Baseline PET scans should also help to improve interpretation of bone marrow involvement, which can be quite prominent in scans obtained during treatment due to bone marrow stimulation caused by chemo-immunotherapy.
False positive findings at the site of residual masses may be seen due to rebound thymic hyperplasia or post therapy inflammatory changes in lymph nodes or mediastinal/ pulmonary tissue, with the latter apparently substantially more frequent following radiation therapy than after chemotherapy or chemoimmunotherapy. 11;12 Overscore concerning lung lesions were relatively frequent due to bulky mediastinal disease, interpreted as pulmonary lesions. CT readings in patients with Hodgkin's disease and they also proposed for standardization of CT reporting. 13 Even though in nuclear medicine and radiology many test results depend on visual detection and interpretation of individual observers, and observer variation is considered to be the Achilles' heel of the trade, there is a lack of observer variation data with multiple readers (as opposed to limited analyses coming with observational, and often single-center, studies). 14 
CONCLUSION
Interobserver variability in FDG PET readings in lymphoma was higher than anticipated. This variability may affect patient management and the results of clinical trials. A standardized method of reporting is urgently needed to improve consistency. Moreover PET-CT technology might improve the specificity of interpretations. Availability of baseline scans night also contribute to improve PET readings in these patients.
